HCW Biologics Says It Received USPTO Notice Of Allowance For Claims Covering Use Of HCW9302 To Treat Alopecia Areata; Says Phase 1 Monotherapy Study On Track For Q4 2026 Completion

Benzinga Newsdesk www.benzinga.com Positive 73.2%

Neg 0% Neu 0% Pos 73.2%

Comments

No comments yet. Be the first!